Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-04-30

Unicycive Therapeutics (UNCY)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,391,621
Shalabh Gupta total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
Say-on-pay support, latest vote
Companies that benchmark against UNCY
No companies currently name UNCY as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Shalabh Gupta$572,000$486,200$0$1,333,421$0$0$0$2,391,621
Chief Executive Officer
Doug Jermasek363,00077,138041,028000481,166
Executive VP, Corporate Strategy

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Shalabh Gupta$2,391,621$2,439,884−48,263
Doug Jermasek481,166873,346−392,180

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Shalabh GuptaOption1,9717.5
Shalabh GuptaOption146,4007.5
Shalabh GuptaOption76,97711.4
Shalabh GuptaOption15,5263.4
Shalabh GuptaOption325,0004.71
Shalabh GuptaOption6427.5
Shalabh GuptaOption42,3447.5
Shalabh GuptaOption27,02411.4
Shalabh GuptaOption5,4503.4
Shalabh GuptaOption90,0004.71
Doug JermasekOption1,2617.5
Doug JermasekOption42,3447.5
Doug JermasekOption27,02411.4
Doug JermasekOption5,4503.4
Doug JermasekOption10,0004.71
05

Incentive-plan design — the Compensation Discussion & Analysis

The Compensation Committee recommends to the Board for approval the overall compensation philosophy for the company and periodically reviews it to ensure it is appropriate and does not incentivize unnecessary and excessive risk taking. Executive compensation consists of base salary, annual discretionary bonuses based on performance objectives, and equity-based compensation awards.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultant
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Gaurav Aggarwal, M.DIndependent · Audit · Compensation (Chair) · Nominating and Governance · Departed during FY$65,000$0$84,486$149,486
Saraswati Kenkare-Mitra, Ph.DIndependent · Audit · Compensation · Nominating and Governance (Chair)63,000084,486147,486
Shalabh Gupta, M.DEmployee director · Board Chair0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$50,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$128,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$128,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Unicycive Therapeutics2025Shalabh Gupta$572,000$0$1,333,421$0$2,391,621

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Shalabh GuptaDEF 14A2026-04-300001213900-26-049690Section “Executive Compensation”. As printed: 2,391,621. Filing ↗machine: r1 · c23 · span 136280–136289
2Section 01, Doug JermasekDEF 14A2026-04-300001213900-26-049690Section “Executive Compensation”. As printed: 481,166. Filing ↗machine: r7 · c23 · span 142267–142274
3Section 08, Gaurav Aggarwal, M.DDEF 14A2026-04-300001213900-26-049690Section “Director Compensation”. As printed: 149,486. Filing ↗
4Section 08, Saraswati Kenkare-Mitra, Ph.DDEF 14A2026-04-300001213900-26-049690Section “Director Compensation”. As printed: 147,486. Filing ↗
5Section 08, Shalabh Gupta, M.DDEF 14A2026-04-300001213900-26-049690Section “Director Compensation”. As printed: 0. Filing ↗
6Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
7Section 09b board cost (computed)ComputedcomputedCash 128,000 + equity 0 + all other 0 = 128,000, summed across the director compensation table rows.machine: formula: Σ = 128,000
8Unicycive Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-300001213900-26-049690CEO total compensation as printed in Unicycive Therapeutics's own proxy. As printed: 2,391,621. Filing ↗machine: r1 · c23 · span 136280–136289